Skip to main content
Smart Investors Daily
DN

NASDAQ · DNLI

Denali Therapeutics Inc.

Healthcare · Biotechnology

$18.45

Up+$0.25 (+1.37%)

Updated Nov 21, 2026, 8:45 PM

SID Score

5.2/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
2.55B
P/E ratio
-6
Dividend yield
0.00%
52-week range
$15.34 – $27.30
Volume
2.63M
Avg. volume
1.72M

Price performance · DNLI

DNLI price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 20, 2026

DNLI closed at $18.45 after 21 trading sessions, up 0.22% for the selected period.

Last close
$18.45
Period change
+0.22%
Period low
$18.00
Period high
$20.96
Daily close
View OHLC price history
DNLI OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 20, 2026$17.97$18.85$17.92$18.452.63M
Nov 19, 2026$18.43$19.00$18.13$18.201.27M
Nov 18, 2026$18.02$18.58$17.915$18.402.37M
Nov 17, 2026$18.11$18.256$17.17$18.001.13M
Nov 16, 2026$18.74$18.861$18.075$18.081.15M
Nov 13, 2026$18.77$19.005$18.34$18.74795.68K
Nov 12, 2026$19.39$19.60$18.795$18.891.31M
Nov 11, 2026$19.905$20.24$19.625$19.73873.56K
Nov 10, 2026$20.01$20.69$19.72$19.85975.85K
Nov 9, 2026$20.34$20.5579$19.7601$20.331.38M
Nov 6, 2026$19.97$20.36$19.78$20.071.59M
Nov 5, 2026$20.96$21.08$19.65$19.722.25M
Nov 4, 2026$21.23$22.19$19.75$20.964.9M
Nov 3, 2026$19.21$19.52$18.98$19.452.43M
Nov 2, 2026$19.11$19.195$18.32$18.861.24M
Oct 30, 2026$19.25$19.635$18.635$18.941.31M
Oct 29, 2026$19.35$19.78$19.14$19.321.45M
Oct 28, 2026$18.92$19.29$18.84$19.291.59M
Oct 27, 2026$18.48$19.32$18.40$19.221.48M
Oct 26, 2026$18.495$18.67$18.35$18.66726.05K
Oct 23, 2026$18.49$18.50$18.005$18.411.01M

Latest DNLI news

The latest Smart Investors Daily articles mentioning DNLI.

DNLI research

Overview

Company profile and research snapshot.

Company profile

Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$33.50
Implied upside
—
Analysts
—
DNLI recent ratings
DateFirmRatingTarget
Nov 13, 2026Morgan StanleyOverweight—
Nov 13, 2026Wells FargoOverweight—
Nov 4, 2026Morgan StanleyOverweight—
Nov 4, 2026WedbushOutperform—
Nov 4, 2026BTIGBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Feb 26, 2026

Denali Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights

Tividenofusp alfa (DNL310; ETV:IDS) launch readiness established ahead of April 5, 2026 Prescription Drug User Fee Act (PDUFA) target action date for Hunter syndromeDNL126 (ETV:SGSH) Phase 1/2 preliminary data presented at 2026 WORLDSymposium™, supporting plans to pursue an accelerated approval path in Sanfilippo syndrome type AStart-up activities underway for DNL628 (OTV:MAPT) Phase 1b study for Alzheimer's disease and DNL952 (ETV:GAA) Phase 1 study for late-onset Pompe diseaseTransportVehicle™

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.